
'use server';

/**
 * Extracts the main content from a given URL.
 * For now, this is a placeholder and returns a dummy text.
 * In a real application, this would use a library like Cheerio or a headless browser
 * to scrape and clean the article content.
 */
export async function extractArticleContent(url: string): Promise<string> {
  console.log(`Extracting content from: ${url}`);
  
  // This is a mock implementation.
  // A real implementation would involve fetching the URL and parsing the HTML.
  // For example, using a library like `node-html-parser` or a service.
  return `
    This is a placeholder for the extracted content of the article at ${url}.
    The full article would be scraped and processed here.
    For the purpose of this demo, we are using a simplified summary.

    The study aimed to evaluate the efficacy and safety of a novel drug, "CogniBoost,"
    in patients with mild to moderate Alzheimer's disease. The trial was a multi-center,
    randomized, double-blind, placebo-controlled study conducted over 18 months.

    A total of 500 patients were enrolled. The primary endpoint was the change from baseline
    in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) score.
    Secondary endpoints included changes in the Clinical Dementia Rating (CDR) scale and
    activities of daily living.

    Results showed a statistically significant improvement in the ADAS-Cog score for the
    CogniBoost group compared to the placebo group (p < 0.01). However, no significant
    difference was observed in the CDR scale. The drug was generally well-tolerated,
    with the most common adverse events being nausea and headache.

    Further research is needed to understand the long-term effects and clinical significance
    of these findings.
  `;
}
